Heart transplantation has become standard of care for end-stage heart failure. Challenges include the limited supply of donor organs and the increased complexity of heart transplant candidates who are at higher risk for poor outcomes. Recent advances may address these challenges, including proposed changes in heart transplant allocation policy, a better understanding of the definition and management of primary graft dysfunction, and advances in the management of sensitized heart transplant candidates. Developments in these areas may result in more equitable distribution and expansion of the donor pool and improved quality of life and survival for heart transplant recipients.
Keywords: Bortezomib; Eculizumab; Heart transplant allocation; Heart transplantation; Primary graft dysfunction; Rituximab; Sensitization.
Copyright © 2016 Elsevier Inc. All rights reserved.